Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Public Health

Drug-facilitated date rape

Erica Weir
CMAJ July 10, 2001 165 (1) 80;
Erica Weir
CMAJ
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

Epidemiology: Date-rape drugs cause sedation and amnesia to the extent that their victims cannot resist or may not be aware of a sexual assault. About 25% of the 1400 women who contact the Canadian Sexual Assault Centre each year report that drugs were a factor in a rape.1 Drug-facilitated rape is most commonly linked to the surreptitious administration of flunitrazepam (Rohypnol) or of a newer arrival, gamma hydroxybutyrate acid (GHB). Reports from the police and emergency departments suggest that use of these drugs, particularly GHB, in sexual assaults is increasing.2 Routine tests to detect the drugs are not widely available, prompting one Ontario Liberal MPP to push the province to provide immediate testing for women who suspect they have been victims of date rape.

Well intentioned though that initiative may be, widespread testing is already available for the drugs most commonly used in date rape: alcohol, marijuana, benzodiazepines, cocaine, heroin and amphetamines. Any substance that is administered to lower sexual inhibition and enhance the possibility of unwanted sexual intercourse is potentially a date-rape drug. Of 2003 urine samples submitted by rape treatment centres across the United States within 72 hours of a suspected drug-facilitated rape, GHB was detected in only 3% of the samples and flunitrazepam in less than 1%; alcohol was detected in 69% of the samples, marijuana in 18% and cocaine in 5%.3 Physicians should be aware of the mechanisms and clinical management of flunitrazepam and GHB intoxication, but they should also be aware that, when a drug-facilitated rape is suspected, alcohol is the substance most likely involved.

Clinical management: Flunitrazepam (Rohypnol, “roofies,” “rope,” the “forget pill”) is an extremely potent benzodiazepine. It is used legally as an adjunct for general anesthesia in 62 countries in Europe, Africa, Latin America and the Middle East. It is not approved for general marketing as a therapeutic agent in Canada or the United States. Most of the tablets circulated in Canada are produced illegally in Mexico and Latin America. They are packaged in foil-backed, clear plastic blister packs and sold for about $2 per 1- or 2-mg tablet. When dissolved in a drink, flunitrazepam is odourless and tasteless. It is rapidly absorbed and takes effect 20–30 minutes after ingestion.2

The drug produces symptoms similar to alcohol intoxication and should be suspected in any sexual assault involving a person who appears intoxicated or has amnesia. Physicians, in addition to adhering to standard rape protocols, should ensure that a urine specimen is analyzed for flunitrazepam metabolites. Provincial poison control centres (listed in the lavender section of the Compendium of Pharmaceuticals and Specialties) can advise on specimen collection and testing.2 Unless the drug is taken with alcohol, overdoses are rarely fatal. The specific benzodiazepine antagonist flumazenil can be used to reverse coma induced by flunitrazepam.4

GHB (“liquid ecstasy,” “grievous bodily harm,” “scoop”) is a metabolite of the inhibitory neurotransmitter gamma-aminobutyric acid. A central nervous system depressant, it was developed as an anesthetic but has also been used to treat narcolepsy and alcohol withdrawal, and bodybuilders have used it to stimulate muscle growth. Inexpensive and easy to synthesize, it can be produced from common ingredients using recipes obtainable on the Internet. Available as a powder or a liquid, GHB is colourless and odourless but may have a distinct salty taste. Taken in small doses it lowers inhibition and instills feelings of calmness and euphoria. In higher doses it produces drowsiness, dizziness, amnesia, confusion, hallucinations, nausea and vomiting. Symptoms appear within 15 minutes of administration. Ingestion of 2 g results in a deep sleep and 4 g results in coma. If it is mixed in alcoholic beverages, the 2 sedatives are synergistic. There is no antidote for GHB; treatment is supportive.3

When GHB intoxication is suspected, a urine specimen (100 mL in a sterile container) should be collected. The half-life of GHB is 27 minutes, so a specimen collected more then 96 hours after the event may be of little value. If the assault occurred within the previous 24 hours, blood should also be collected and refrigerated in a grey-top tube containing sodium fluoride and potassium oxalate.3

Prevention: Precautions to avoid drug-facilitated rape include drinking beverages slowly, keeping an eye on and mixing one's own drinks, watching as the drink is poured and obtaining a fresh one after leaving the drink unattended (e.g., after dancing).

Figure

Figure. Order a new drink after dancing Photo by: Canapress

References

  1. 1.↵
    Gorin T. A rape crisis centre view of Rohypnol: how the hype tricks raped women. Vancouver: Canadian Association of Sexual Assault Centres. Available: www.casac.ca/rohypnol.htm (accessed 2001 June 8).
  2. 2.↵
    Schwartz R, Milteer R, LeBeau M. Drug-facilitated sexual assault. South Med J 2000;93:558-61.
    OpenUrlCrossRefPubMed
  3. 3.↵
    Slaughter L. Involvement of drugs in sexual assault. J Reprod Med 2000;45:425-30.
    OpenUrlPubMed
  4. 4.↵
    Schwartz R, Weaver A. Rohypnol, the date rape drug. Clin Pediatr 1998;37:321-2.
    OpenUrlFREE Full Text
PreviousNext
Back to top

In this issue

CMAJ
Vol. 165, Issue 1
10 Jul 2001
  • Table of Contents
  • Index by author
  • Canadian Adverse Drug Reaction Newsletter (81-88)

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Drug-facilitated date rape
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Drug-facilitated date rape
Erica Weir
CMAJ Jul 2001, 165 (1) 80;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Drug-facilitated date rape
Erica Weir
CMAJ Jul 2001, 165 (1) 80;
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • References
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Drug-facilitated sexual assault
  • Google Scholar

More in this TOC Section

  • Seasonal drinking: Let's avoid the “January effect”
  • Influenza in children
  • Latent tuberculosis: revised treatment guidelines
Show more Public Health

Similar Articles

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

CMA Civility, Accessibility, Privacy

 

Powered by HighWire